SCHEMBL4434192

SCHEMBL4434192

O=[N+]([O-])c1ccc(OP(=O)(O)CNS(=O)(=O)c2ccc(Br)s2)cc1.[NaH]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 3/20 0.45
CA1 P00915 2/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.40
MAPK1 P28482 2/20 0.40
POLB P06746 1/20 0.39
LMNA P02545 3/20 0.39
GALR3 O60755 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
TSHR P16473 2/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
MAPT P10636 3/20 0.38
CA12 O43570 1/20 0.38
MMP2 P08253 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4420572 0.82 CA2 (0.55) CA2CA1CES2CES1SMN1; SMN2
SCHEMBL4431396 0.81 CA1 (0.46) CA2CA1CES2CES1RAB9A
SCHEMBL3222070 0.80 CA1 (0.47) CA2CA1CES2CES1RAB9A
SCHEMBL6380631 0.79 CA2 (0.46) CA2CA1CES2CES1SMN1; SMN2
SCHEMBL6382392 0.78 ALDH1A1 (0.52) CA2CA1CES2CES1SMN1; SMN2
SCHEMBL1686914 0.78 CA2 (0.42) CA2CA1CES2CES1SMN1; SMN2
SCHEMBL4419753 0.77 FLT1 (0.52) CA2CA1CES2CES1HTT
SCHEMBL4427321 0.77 GAA (0.56) CA2CA1CES2CES1SMN1; SMN2
SCHEMBL4422627 0.77 KMT2A (0.58) CA2CA1CES2CES1HTT
SCHEMBL4427284 0.77 GAA (0.50) CA2CA1CES2CES1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514556-B2 Inhibitors of β-lactamase METHYLGENE INC. (CA) 2009-04-07 US disclosed
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase METHYLGENE, INC. (CA) 2007-12-20 US disclosed
US-7259172-B2 phenyl or thien-2-yl substituted amide methyl phosphonate or phosphonyl halide derivatives; do not require a beta -lactam pharmacophore; bactericides; antibiotic resistance METHYLGENE INC. (CA) 2007-08-21 US disclosed
US-20060105999-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2006-05-18 US disclosed
US-7030103-B2 Sulfonamidomethyl phosphonate inhibitors of β-lactamase METHYLGENE, INC. (CA) 2006-04-18 US disclosed
EP-1194436-B1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE METHYLGENE INC (CA) 2005-11-30 EP disclosed
US-6921756-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-07-26 US disclosed
US-6884791-B2 Inhibitors of β-lactamase METHYLGENE, INC. (CA) 2005-04-26 US disclosed
US-20050043276-A1 Novel inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2005-02-24 US disclosed
WO-2004048393-A2 NOVEL INHIBITORS OF β-LACTAMASE METHYLGENE, INC. (CA) 2004-06-10 WO disclosed
US-20040082546-A1 Novel Inhibitors of beta-lactamase METHYLGENE, INC. 2004-04-29 US disclosed
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-03-25 US disclosed
US-20040029836-A1 Novel inhibitors of beta-lactamase 92229129 QUEBEC INC. (CA) 2004-02-12 US disclosed
US-6472406-B1 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase METHYLGENE, INC. (CA) 2002-10-29 US disclosed
EP-1194436-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF BETA-LACTAMASE Methylgene, Inc. (CA) 2002-04-10 EP disclosed
WO-2001002411-A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE METHYLGENE INC. (CA) 2001-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043276-A1 Novel inhibitors of beta-lactamase MGAM, LSS, CYP51A1 CA2 2716/4885CA1 4384/4885CES2 174/4885
US-20040029836-A1 Novel inhibitors of beta-lactamase LSS, MGAM, COASY CA2 2629/4885CA1 4178/4885CES2 176/4885
US-20060105999-A1 Novel inhibitors of beta-lactamase LSS, MGAM, LCT CA2 2457/4885CA1 4321/4885CES2 178/4885
US-20040059115-A1 Novel sulfonamidomethyl phosphonate inhibitors of beta-lactamase PGLS, MGAM, STS CA2 2859/4885CA1 4176/4885CES2 324/4885
US-20070293675-A1 Novel Inhibitors Of Beta-Lactamase MGAM, LSS, CYP51A1 CA2 2716/4885CA1 4384/4885CES2 174/4885
US-20040082546-A1 Novel Inhibitors of beta-lactamase LSS, MGAM, COASY CA2 2498/4885CA1 4194/4885CES2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.